Australia markets open in 2 hours 11 minutes

Zydus Lifesciences Limited (ZYDUSLIFE.NS)

NSE - NSE Real-time price. Currency in INR
Add to watchlist
1,074.00-12.05 (-1.11%)
At close: 03:30PM IST
Currency in INR

Valuation measures4

Market cap (intra-day) 1.08T
Enterprise value 1.07T
Trailing P/E 28.38
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)5.72
Price/book (mrq)5.46
Enterprise value/revenue 5.63
Enterprise value/EBITDA 18.93

Trading information

Stock price history

Beta (5Y monthly) 0.55
52-week change 3110.14%
S&P500 52-week change 326.14%
52-week high 31,172.50
52-week low 3498.85
50-day moving average 3992.89
200-day moving average 3773.18

Share statistics

Avg vol (3-month) 31.47M
Avg vol (10-day) 32.09M
Shares outstanding 51.01B
Implied shares outstanding 61.02B
Float 8250.46M
% held by insiders 175.13%
% held by institutions 113.68%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 43
Forward annual dividend yield 40.28%
Trailing annual dividend rate 33.00
Trailing annual dividend yield 30.28%
5-year average dividend yield 40.83
Payout ratio 415.83%
Dividend date 3N/A
Ex-dividend date 425 July 2024
Last split factor 25:1
Last split date 306 Oct 2015

Financial highlights

Fiscal year

Fiscal year ends 31 Mar 2024
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 19.74%
Operating margin (ttm)25.66%

Management effectiveness

Return on assets (ttm)10.31%
Return on equity (ttm)18.90%

Income statement

Revenue (ttm)195.47B
Revenue per share (ttm)193.17
Quarterly revenue growth (yoy)18.60%
Gross profit (ttm)N/A
EBITDA 53.03B
Net income avi to common (ttm)38.36B
Diluted EPS (ttm)37.88
Quarterly earnings growth (yoy)298.60%

Balance sheet

Total cash (mrq)13.58B
Total cash per share (mrq)13.43
Total debt (mrq)8.04B
Total debt/equity (mrq)3.64%
Current ratio (mrq)2.15
Book value per share (mrq)196.10

Cash flow statement

Operating cash flow (ttm)32.28B
Levered free cash flow (ttm)15.23B